Sergio España-Cueto
@ecuetosergio.bsky.social
He/Him | MD, PhD, MSc | Germans Trias University Hospital & Fight Infections Foundation | MSF | Infectious Diseases, Tropical Medicine & Global Health | Field Clinical Research Enthusiast | Photography & Science
The AiDx Assist device offers a reliable and efficient alternative to manual microscopy. Its automation reduces the need for training and minimizes human error. The AiDx Assist device could enhance early detection and treatment, potencially transforming Schistosomiasis diagnosis in endemic regions.
March 22, 2025 at 9:29 AM
The AiDx Assist device offers a reliable and efficient alternative to manual microscopy. Its automation reduces the need for training and minimizes human error. The AiDx Assist device could enhance early detection and treatment, potencially transforming Schistosomiasis diagnosis in endemic regions.
#longcovid #postcovidcondition #covid19 #infectiousdiseases #research #naturecommunications #nature #covidpersistente #condicionpostcovid19
March 21, 2025 at 1:20 PM
☄️ Here is our recent publication!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial - Nature Communications
Here, the authors report results from a clinical trial testing whether therapeutic plasma exchange (TPE) can help people with post-COVID-19 condition (PCC). While TPE had a favorable safety profile, i...
www.nature.com
March 21, 2025 at 10:46 AM
☄️ Here is our recent publication!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
The Editors’ Highlights showcase the 50 most outstanding papers in each field, emphasizing the significance of our research on post-COVID syndrome treatment.
Grateful to Nature Communications for this recognition and invite you to read and share our work with colleagues who may be interested !
Grateful to Nature Communications for this recognition and invite you to read and share our work with colleagues who may be interested !
March 21, 2025 at 10:42 AM
The Editors’ Highlights showcase the 50 most outstanding papers in each field, emphasizing the significance of our research on post-COVID syndrome treatment.
Grateful to Nature Communications for this recognition and invite you to read and share our work with colleagues who may be interested !
Grateful to Nature Communications for this recognition and invite you to read and share our work with colleagues who may be interested !
PCR and UCP-LF CAA were more sensitive for S. haematobium, while PCR and POC-CCA worked best for S. mansoni. This suggests that different regions may need different testing strategies?
March 18, 2025 at 6:48 PM
PCR and UCP-LF CAA were more sensitive for S. haematobium, while PCR and POC-CCA worked best for S. mansoni. This suggests that different regions may need different testing strategies?
For S. mansoni:
• 59% (PCR)
• 55% (UCP-LF CAA)
• 54% (POC-CCA)
• 59% (PCR)
• 55% (UCP-LF CAA)
• 54% (POC-CCA)
March 18, 2025 at 6:48 PM
For S. mansoni:
• 59% (PCR)
• 55% (UCP-LF CAA)
• 54% (POC-CCA)
• 59% (PCR)
• 55% (UCP-LF CAA)
• 54% (POC-CCA)
For S. haematobium, detection rates were:
• 66% (PCR)
• 60% (UCP-LF CAA)
• 52% (POC-CCA)
• 66% (PCR)
• 60% (UCP-LF CAA)
• 52% (POC-CCA)
March 18, 2025 at 6:48 PM
For S. haematobium, detection rates were:
• 66% (PCR)
• 60% (UCP-LF CAA)
• 52% (POC-CCA)
• 66% (PCR)
• 60% (UCP-LF CAA)
• 52% (POC-CCA)
March 3, 2025 at 11:11 PM
These results highlight the need for continued research into therapeutic strategies for Long COVID and understanding its pathophysiology. Huge thanks to @lmateu.bsky.social, @rutgerwalls.bsky.social & the entire Long COVID team from @fundaciolluita.bsky.social for trusting me from the very beginning
March 3, 2025 at 10:27 PM
These results highlight the need for continued research into therapeutic strategies for Long COVID and understanding its pathophysiology. Huge thanks to @lmateu.bsky.social, @rutgerwalls.bsky.social & the entire Long COVID team from @fundaciolluita.bsky.social for trusting me from the very beginning
Our findings confirmed that TPE is a safe procedure, with a similar safety profile in both groups. However, we did not observe any significant clinical improvements across the evaluated efficacy parameters compared to the placebo group
March 3, 2025 at 10:20 PM
Our findings confirmed that TPE is a safe procedure, with a similar safety profile in both groups. However, we did not observe any significant clinical improvements across the evaluated efficacy parameters compared to the placebo group
🟠 In this trial, 50 patients with Long COVID were randomized to receive 6 sessions of either Plasma Exchange or Placebo, with a 90D follow-up. Our primary endpoint was safety, and secondary endpoints functional status, symptomology, quality of life, neurocognitive symptoms, and analytical parameters
March 3, 2025 at 10:19 PM
🟠 In this trial, 50 patients with Long COVID were randomized to receive 6 sessions of either Plasma Exchange or Placebo, with a 90D follow-up. Our primary endpoint was safety, and secondary endpoints functional status, symptomology, quality of life, neurocognitive symptoms, and analytical parameters